New drug combo tested for Tough-to-Treat lung cancer
Disease control
Terminated
This early-phase study tested a new combination of two investigational drugs, AK119 and AK112, with or without chemotherapy, for people with advanced non-small cell lung cancer. The cancer had a specific genetic change (EGFR mutation) and had stopped responding to standard target…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC